Kerstin Gnirß

Kerstin Gnirß

Auto-generated profile, based on publicly available information

Kerstin Gnirß

Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
TTTheodros Solomon Tsegaye
Theodros Solomon Tsegaye
KGKerstin Gnirß
Kerstin Gnirß
NRNiels Rahe-Meyer
Niels Rahe-Meyer
MKMiriam Kiene
Miriam Kiene
AKAnnika Krämer-Kühl
Annika Krämer-Kühl
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
Background: Platelets, anucleate cell fragments abundant in human blood, can capture HIV-1 and platelet counts have been associated with viral load and disease progression. However, the impact of platelets on HIV-1 infection of T cells is unclear. Results: We found that platelets suppress HIV-1 spread in co-cultured T cells in a concentration-dependent manner. Platelets containing granules inhibited HIV-1 spread in T cells more efficiently than degranulated platelets, indicating that the granule content might exert antiviral activity. Indeed, supernatants from activated and thus degranulated platelets suppressed HIV-1 infection. Infection was inhibited at the stage of host cell entry and inhibition was independent of the viral strain or coreceptor tropism. In contrast, blockade of HIV-2 and SIV entry was less efficient. The chemokine CXCL4, a major component of platelet granules, blocked HIV-1 entry and neutralization of CXCL4 in platelet supernatants largely abrogated their anti-HIV-1 activity. Conclusions: Release of CXCL4 by activated platelets inhibits HIV-1 infection of adjacent T cells at the stage of virus entry. The inhibitory activity of platelet-derived CXCL4 suggests a role of platelets in the defense against infection by HIV-1 and potentially other pathogens.

9 April 2014 in Viruses
Verified
Journal Article
Open access
PDF file
KGKerstin Gnirß
Kerstin Gnirß
MFMarie Fiedler
Marie Fiedler
AKAnnika Krämer-Kühl
Annika Krämer-Kühl
SBSebastian Bolduan
Sebastian Bolduan
EMEva Mittler
Eva Mittler
Stefan PöhlmannStefan Pöhlmann
Stefan Pöhlmann
The host cell protein tetherin can restrict the release of enveloped viruses from infected cells. The HIV-1 protein Vpu counteracts tetherin by removing it from the site of viral budding, the plasma membrane, and this process depends on specific interactions between the transmembrane domains of Vpu and tetherin. In contrast, the glycoproteins (GPs) of two filoviruses, Ebola and Marburg virus, antagonize tetherin without reducing surface expression, and the domains in GP required for tetherin counteraction are unknown. Here, we show that filovirus GPs depend on the presence of their authentic transmembrane domains for virus-cell fusion and tetherin antagonism. However, conserved residues within the transmembrane domain were dispensable for membrane fusion and tetherin counteraction. Moreover, the insertion of the transmembrane domain into a heterologous viral GP, Lassa virus GPC, was not sufficient to confer tetherin antagonism to the recipient. Finally, mutation of conserved residues within the fusion peptide of Ebola virus GP inhibited virus-cell fusion but did not ablate tetherin counteraction, indicating that the fusion peptide and the ability of GP to drive host cell entry are not required for tetherin counteraction. These results suggest that the transmembrane domains of filoviral GPs contribute to tetherin antagonism but are not the sole determinants.